Groneberg David A, Harrison Selena, Dinh Q Thai, Geppetti Pierangelo, Fischer Axel
Otto-Heubner-Centre, Pneumology and Immunology, Charité-Universitätsmedizin Berlin, Germany.
Curr Drug Targets. 2006 Aug;7(8):1005-10. doi: 10.2174/138945006778019318.
Tachykinins as substance P and neurokinin A belong to a family of peptides, which are released from airway nerves after noxious stimulation. They influence numerous respiratory functions under both normal and pathological conditions including the regulation of airway smooth muscle tone, vascular tone, mucus secretion and immune functions. For the most part the synthesis/release of tachykinins is associated with neuronal cells; nevertheless, inflammatory and immune cells can synthesize and release tachykinins under certain physiological conditions. Moreover, this second cellular source of tachykinins may play an important role in inflammatory airway diseases such as bronchial asthma or chronic obstructive pulmonary disease (COPD). Dual tachykinin (NK1 and NK2) receptor antagonists demonstrate a significant bronchoprotection and a possible future role in the development of novel therapeutic approaches. In addition, NK3 receptors could also possess a bronchoprotective action, however, their presence in the human respiratory tract still needs to be confirmed. The family of tachykinins has recently been extended by the discovery of a third tachykinin gene that encodes the previously unknown NK1 receptor selective tachykinins hemokinin 1, endokinin A and B. Together with other novel tachykinin peptides such as C14TKL-1 and virokinin further research is required to define their respiratory biological role in health and disease.
速激肽如P物质和神经激肽A属于一类肽,在有害刺激后从气道神经释放。它们在正常和病理条件下影响多种呼吸功能,包括气道平滑肌张力、血管张力、黏液分泌和免疫功能的调节。在很大程度上,速激肽的合成/释放与神经细胞相关;然而,炎症和免疫细胞在某些生理条件下也能合成和释放速激肽。此外,速激肽的这第二种细胞来源可能在炎症性气道疾病如支气管哮喘或慢性阻塞性肺疾病(COPD)中起重要作用。双重速激肽(NK1和NK2)受体拮抗剂显示出显著的支气管保护作用,并可能在新型治疗方法的开发中发挥未来作用。此外,NK3受体也可能具有支气管保护作用,然而,它们在人类呼吸道中的存在仍有待证实。最近发现了第三个速激肽基因,其编码此前未知的对NK1受体有选择性的速激肽——血激肽1、内激肽A和B,这使得速激肽家族得到了扩展。连同其他新型速激肽肽如C14TKL-1和病毒激肽一起,需要进一步研究来确定它们在健康和疾病中的呼吸生物学作用。